Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin at -4597.1%

Net margin was -4597.1% in Q2 FY2026.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-4597.1%— QoQ
Last fiscal yearDec 2025
-4490.9%— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-4490.9%
Year-over-year change
—

Net Margin vs competitors

How ATTO compares with its peers on the latest reported figures

  • ATTO's FY2025 net margin of -4490.9% is the 5th highest of the 7 companies compared; the peer median is -796.2%.
ATTO Competitors Peer median
Net Margin for ATTO and competitors
Company Period LTM level YoY 3-year change
QTTBQ32 Bio Inc.LTM Mar 202661.9% —+699.1 pp
ANABAnaptysBio, Inc.LTM Mar 2026-11.5% +114.2 pp+1245.7 pp
EVMNEvommune, Inc.LTM Mar 2026-759.9% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-832.6% -100.2 pp-537.5 pp
ATTOAttovia Therapeutics, Inc.FY2025-4490.9% ——
ALMSAlumis Inc. Common StockLTM Jun 2026-5933.5% -4799.0 pp—
CNTBConnect Biopharma Holdings LimitedFY2025-86687.5% -86627.5 pp—
ORKAOruka Therapeutics, Inc.FY2025— ——
MLTXMoonLake ImmunotherapeuticsFY2025— ——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
ZURAZura Bio LimitedFY2025— ——
Peer median (excluding ATTO) -796.2%-2449.6 pp+699.1 pp

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.